Lexicon Pharmaceuticals(US:LXRX)2025-11-06 12:33Financial Performance - Total revenues for Q3 2025 increased to $14.2 million from $1.8 million in Q3 2024, representing a growth of approximately 688.9%[9] - Net loss for Q3 2025 was $12.8 million, or $0.04 per share, compared to a net loss of $64.8 million, or $0.18 per share, in Q3 2024[12] - As of September 30, 2025, Lexicon had $145.0 million in cash and investments, down from $238.0 million as of December 31, 2024[13] Expenses - Research and development expenses decreased to $18.8 million in Q3 2025 from $25.8 million in Q3 2024, a reduction of about 27.1%[10] - Selling, general and administrative expenses decreased significantly to $7.6 million in Q3 2025 from $39.6 million in Q3 2024, a decline of approximately 80.9%[11] Clinical Development - Lexicon completed all IND-enabling studies of LX9851 for obesity, with Novo Nordisk preparing for IND submission, potentially triggering up to an additional $30 million in milestone payments[9] - Pilavapadin demonstrated a two-point reduction in average daily pain scores by week 12 in the PROGRESS Phase 2b study for diabetic peripheral neuropathic pain[4] - Enrollment in the SONATA-HCM Phase 3 study is on target for completion in 2026, with 130 sites initiated across 20 countries[9] - Lexicon submitted new data to the FDA supporting the benefit-risk profile of Zynquista for type 1 diabetes, expecting regulatory feedback in Q4 2025[9] Licensing Agreements - An exclusive licensing agreement for LX9851 with Novo Nordisk included an upfront payment of $45 million and potential total payments of up to $1 billion[9]